Perospiron

Perospiron
(IUPAC) ime
	(3aR,7aS)-24-[4-(1,2-benzizotiazol-3-il)piperazin-1-il]butil}heksahidro-1H-izoindol-1,3(2H)-dion
Klinički podaci
Robne marke	Lulan
AHFS/Drugs.com	Internacionalno ime leka
Identifikatori
CAS broj	150915-41-6
ATC kod	nije dodeljen
PubChem	115368
ChemSpider	16737064
UNII	N303OK87DT
Hemijski podaci
Formula	C23H30N4O2S
Mol. masa	426,57 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C24H32N4O2S/c29-23-20-9-3-4-10-21(20)24(30)28(23)12-6-5-11-26-13-15-27(16-14-26)22-19-8-2-1-7-18(19)17-31-25-22/h1-2,7-8,20-21H,3-6,9-17H2/t20-,21+ ; Key: GTAIPSDXDDTGBZ-OYRHEFFESA-N
Farmakokinetički podaci
Poluvreme eliminacije	2-2,5 sata
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	℞ Prescription only
Način primene	Oralnot

Perospiron (Lulan) je atipični antipsihotik iz azapironske hemijske klase.^[4] Njega je razvila japanska kompanija Dajnipon sumitomo farma 2001 za lečenje šizofrenije i akutne bipolarne manije.^[5]^[6] Perospiron deluje kao parcijalni agonist 5-HT_1A receptora, inverzni agonist 5-HT_2A receptora i antagonist D₂, D₄ i α₁-adrenergičkog receptora.^[7]^[8]^[9]^[10]

Reference[uredi | uredi kôd]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. http://www.jcheminf.com/content/2/1/3. edit
↑ Onrust SV, McClellan K (2001). „Perospirone”. CNS Drugs 15 (4): 329–37; discussion 338. DOI:10.2165/00023210-200115040-00006. PMID 11463136.
↑ de Paulis T (January 2002). „Perospirone (Sumitomo Pharmaceuticals)”. Current Opinion in Investigational Drugs (London, England : 2000) 3 (1): 121–9. PMID 12054062.
↑ „Sumitomo Pharmaceuticals 2001 | News Release | Dainippon Sumitomo Pharma”. Arhivirano iz originala 2006-02-24. https://web.archive.org/web/20060224145409/http://www.ds-pharma.co.jp/english/news/sumitomo_2001/no_002.html.
↑ Hirose A, Kato T, Ohno Y, et al. (July 1990). „Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions”. Japanese Journal of Pharmacology 53 (3): 321–9. DOI:10.1254/jjp.53.321. PMID 1975278. http://www.ncbi.nlm.nih.gov/pubmed/1975278.
↑ Kato T, Hirose A, Ohno Y, Shimizu H, Tanaka H, Nakamura M (December 1990). „Binding profile of SM-9018, a novel antipsychotic candidate”. Japanese Journal of Pharmacology 54 (4): 478–81. DOI:10.1254/jjp.54.478. PMID 1982326. http://www.ncbi.nlm.nih.gov/pubmed/1982326.
↑ Odagaki Y, Toyoshima R (2007). „5-HT1A receptor agonist properties of antipsychotics determined by [35SGTPgammaS binding in rat hippocampal membranes”]. Clinical and Experimental Pharmacology & Physiology 34 (5–6): 462–6. DOI:10.1111/j.1440-1681.2007.04595.x. PMID 17439416. Arhivirano iz originala 2013-01-05. https://archive.is/20130105064942/http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0305-1870&date=2007&volume=34&issue=5-6&spage=462. Pristupljeno 2014-04-05.
↑ Seeman P, Tallerico T (March 1998). „Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors”. Molecular Psychiatry 3 (2): 123–34. DOI:10.1038/sj.mp.4000336. PMID 9577836.

Vidi još[uredi | uredi kôd]

Azapiron

Spoljašnje veze[uredi | uredi kôd]

	Portal Medicina
	Portal Hemija

Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. http://www.jcheminf.com/content/2/1/3. edit

[pmid11463136-4] Onrust SV, McClellan K (2001). „Perospirone”. CNS Drugs 15 (4): 329–37; discussion 338. DOI:10.2165/00023210-200115040-00006. PMID 11463136.

[pmid12054062-5] Paulis T (January 2002). „Perospirone (Sumitomo Pharmaceuticals)”. Current Opinion in Investigational Drugs (London, England : 2000) 3 (1): 121–9. PMID 12054062.

[urlSumitomo_Pharmaceuticals_2001_|_News_Release_|_Dainippon_Sumitomo_Pharma-6] „Sumitomo Pharmaceuticals 2001 | News Release | Dainippon Sumitomo Pharma”. Arhivirano iz originala 2006-02-24. https://web.archive.org/web/20060224145409/http://www.ds-pharma.co.jp/english/news/sumitomo_2001/no_002.html.

[pmid1975278-7] Hirose A, Kato T, Ohno Y, et al. (July 1990). „Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions”. Japanese Journal of Pharmacology 53 (3): 321–9. DOI:10.1254/jjp.53.321. PMID 1975278. http://www.ncbi.nlm.nih.gov/pubmed/1975278.

[pmid1982326-8] Kato T, Hirose A, Ohno Y, Shimizu H, Tanaka H, Nakamura M (December 1990). „Binding profile of SM-9018, a novel antipsychotic candidate”. Japanese Journal of Pharmacology 54 (4): 478–81. DOI:10.1254/jjp.54.478. PMID 1982326. http://www.ncbi.nlm.nih.gov/pubmed/1982326.

[pmid17439416-9] Odagaki Y, Toyoshima R (2007). „5-HT1A receptor agonist properties of antipsychotics determined by [35SGTPgammaS binding in rat hippocampal membranes”]. Clinical and Experimental Pharmacology & Physiology 34 (5–6): 462–6. DOI:10.1111/j.1440-1681.2007.04595.x. PMID 17439416. Arhivirano iz originala 2013-01-05. https://archive.is/20130105064942/http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0305-1870&date=2007&volume=34&issue=5-6&spage=462. Pristupljeno 2014-04-05.

[pmid9577836-10] Seeman P, Tallerico T (March 1998). „Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors”. Molecular Psychiatry 3 (2): 123–34. DOI:10.1038/sj.mp.4000336. PMID 9577836.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

Perospiron

Reference[uredi | uredi kôd]

Vidi još[uredi | uredi kôd]

Spoljašnje veze[uredi | uredi kôd]

Navigacija